Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31549543 | 1.00 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL23919231 | 1.00 | MEN1 (0.31) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8302341 | 0.98 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL10374187 | 0.98 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL23349923 | 0.88 | PHGDH (0.34) | — | |
| SCHEMBL19341401 | 0.86 | OPRD1 (0.32) | — | |
| SCHEMBL6013953 | 0.81 | — | — | |
| Acetic Acid SCHEMBL28367890 | 0.81 | OPRD1 (0.32) | — | |
| SCHEMBL21753956 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL22191150 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272284-B | Method for preparing combretastatin calcium | 东国生命科学株式会社 | 2024-06-21 | — | — | CN | claimed |
| CN-113272284-A | Method for preparing combretastatin calcium | 东国生命科学株式会社 | 2021-08-17 | — | — | CN | claimed |
| WO-1998048844-A2 | ION PARIS, METHOD FOR THE PRODUCTION AND USE THEREOF AS CONTRAST AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-05 | — | — | WO | claimed |
| EP-3819294-B1 | METHOD OF MANUFACTURING GADOBUTROL | ST PHARM CO LTD (KR) | 2026-04-01 | — | — | EP | disclosed |
| CN-119143689-B | Preparation method of combretastatin calcium and intermediate thereof | 苏州美诺医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12180237-B2 | Method for preparing gadobutrol | ST PHARM CO., LTD. (KR) | 2024-12-31 | — | — | US | disclosed |
| CN-119143689-A | Preparation method of combretastatin calcium and intermediate thereof | 苏州美诺医药科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240366803-A1 | LANTHANIDE COMPLEX FORMULATIONS | GE HEALTHCARE AS (NO) | 2024-11-07 | — | — | US | disclosed |
| US-20240358864-A1 | LANTHANIDE COMPLEX FORMULATIONS | GE HEALTHCARE AS (NO) | 2024-10-31 | — | — | US | disclosed |
| CN-113272284-B | Method for preparing combretastatin calcium | 东国生命科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| CN-112585121-B | Process for the preparation of gadobutrol | ST制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| WO-2016105172-A2 | A METHOD FOR PREPARING GADOBUTROL | ST PHARM CO., LTD. (KR) | 2016-06-30 | — | — | WO | disclosed |
| EP-0815091-B1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING AS (NO) | 2002-06-12 | — | — | EP | disclosed |
| EP-0643705-B1 | PROCESS FOR PRODUCING N-beta-g(b)-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,7,10-TETRAAZACYCLODODECANE AND N-beta-g(b)-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,8,11-TETRAAZACYCLOTETRADECANE DERIVATIVES AND THEIR METAL COMPLEXES | SCHERING AG (DE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0815091-A1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING AS (NO) | 1998-01-07 | — | — | EP | disclosed |
| US-5631368-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1997-05-20 | — | — | US | disclosed |
| WO-1996028433-A1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING A.S (NO) | 1996-09-19 | — | — | WO | disclosed |
| EP-0643705-A1 | PROCESS FOR PRODUCING N-$g(b)-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,7,10-TETRAAZACYCLODODECANE AND N-$g(b)-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,8,11-TETRAAZACYCLOTETRADECANE DERIVATIVES AND THEIR METAL COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-03-22 | — | — | EP | disclosed |
| US-5386028-A | Process for the production of N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-31 | — | — | US | disclosed |
| WO-1993024469-A1 | PROCESS FOR PRODUCING N-β-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,7,10-TETRAAZACYCLODODECANE AND N-β-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,8,11-TETRAAZACYCLOTETRADECANE DERIVATIVES AND THEIR METAL COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366803-A1 | LANTHANIDE COMPLEX FORMULATIONS | SLC39A14, ORAI1, SARAF | MEN1 388/4885KMT2A 3051/4885 |
| US-12180237-B2 | Method for preparing gadobutrol | GCG, CCKBR, GUCY1B2 | MEN1 123/4885KMT2A 4054/4885 |
| US-20240358864-A1 | LANTHANIDE COMPLEX FORMULATIONS | SLC39A14, ORAI1, SARAF | MEN1 388/4885KMT2A 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.